Search in:

Leukemia & Lymphoma Volume 53, 2012 - Issue 6

Submit an article Journal homepage

361

Views

CrossRef citations to date

Altmetric

Research Articles

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

Sikander AilawadhiDivision of Hematology, University of Southern California, Los Angeles, CA, USA

Jeff MiecznikowskiDepartment of Biostatistics

Dan P. GaileDepartment of Biostatistics

Dongliang WangDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

Taimur SherDepartment of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

George MulliganMillennium Pharmaceuticals, Cambridge, MA, USA

Barb BryantMillennium Pharmaceuticals, Cambridge, MA, USA

Gregory E. WildingDepartment of Biostatistics

Terry MashtareDepartment of Biostatistics

Leighton SteinDepartment of Biostatistics

Aisha MasoodDepartment of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

Rachel NeuwirthMillennium Pharmaceuticals, Cambridge, MA, USA

Kelvin P. LeeDepartment of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USA

Asher Chanan-KhanDepartment of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USACorrespondence[email protected]

show all

Pages 1174-1182 | Received 05 Jul 2011, Accepted 28 Oct 2011, Published online: 06 Dec 2011

Cite this article
https://doi.org/10.3109/10428194.2011.637212

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Reprints & Permissions

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (14)

Sikander Ailawadhi, Ricardo D. Parrondo, Navnita Dutta, Bing Han, Gina Ciccio, Yesesri Cherukuri, Victoria R. Alegria, Betsy R. LaPlant, Vivek Roy, Taimur Sher, Brett Edwards, Stephanie Lanier, Alak Manna, Keisha Heslop, Thomas Caulfield, Emir Maldosevic, Peter Storz, Rami Manochakian, Yan Asmann, Asher A. Chanan-Khan & Aneel Paulus. (2023) AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. Cancers 15:2, pages 477.
Crossref

Manon Lernoux, Michael Schnekenburger, Mario Dicato & Marc Diederich. (2021) Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochemical Pharmacology 188, pages 114526.
Crossref

Masanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, Shiori Seki, Yoshika Tomonari, Shoutaro Koizumi, Miki Nagatakiya, Mai Katsuyama, Yuuta Yamamoto, Katsumasa Tsurushima, Toshihiko Ishizaka & Shozo Nishida. (2021) Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells. Biomedicines 9:1, pages 33.
Crossref

Masanobu Tsubaki, Tomoya Takeda, Yoshika Tomonari, Kenji Mashimo, Yu‐ichi Koumoto, Sachi Hoshida, Tatsuki Itoh, Motohiro Imano, Takao Satou, Katsuhiko Sakaguchi & Shozo Nishida. (2017) The MIP‐1α autocrine loop contributes to decreased sensitivity to anticancer drugs. Journal of Cellular Physiology 233:5, pages 4258-4271.
Crossref

Bo Tang, Aoshuang Xu, Jian Xu, Haifan Huang, Lei Chen, Yan Su, Lannan Zhang, Junying Li, Fengjuan Fan, Jun Deng, Liang Tang, Chunyan Sun & Yu Hu. (2018) MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. International Journal of Cancer 142:1, pages 109-120.
Crossref

Xin Yue, Yinglin Zuo, Hongpeng Ke, Jiaming Luo, Lanlan Lou, Wenjing Qin, Youqiao Wang, Ziyi Liu, Daoyuan Chen, Haixia Sun, Weichao Zheng, Cuige Zhu, Ruimin Wang, Gesi Wen, Jun Du, Binhua Zhou & Xianzhang Bu. (2017) Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Biochemical Pharmacology 137, pages 29-50.
Crossref

Jiang-Hua Ding, Li-Ya Yuan & Guo-An Chen. (2017) Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT. Oncology Letters 13:2, pages 647-654.
Crossref

Jiusheng Deng, Dongkyoo Park, Mengchang Wang, Ajay Nooka, Qiaoya Deng, Shannon Matulis, Jonathan Kaufman, Sagar Lonial, Lawrence H. Boise, Jacques Galipeau & Xingming Deng. (2016) BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget 7:19, pages 27753-27763.
Crossref

Adil Doganay Duru, Tolga Sutlu, Ann Wallblom, Katarina Uttervall, Johan Lund, Birgitta Stellan, Gösta Gahrton, Hareth Nahi & Evren Alici. (2015) Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLOS ONE 10:9, pages e0138248.
Crossref

Chong Shi, Guo-Bin Zhang & Shu-Wang Yin. (2015) Effect of bortezomib on migration and invasion in cervical carcinoma HeLa cell. Asian Pacific Journal of Tropical Medicine 8:6, pages 485-488.
Crossref

K Chitta, A Paulus, T R Caulfield, S Akhtar, M-KK Blake, S Ailawadhi, J Knight, M G Heckman, A Pinkerton & A Chanan-Khan. (2014) Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer Journal 4:11, pages e260-e260.
Crossref

Jiang-hua Ding, Li-ya Yuan, Rui-Bin Huang & Guo-an Chen. (2014) Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF. European Journal of Haematology 93:4, pages 329-339.
Crossref

Aneel Paulus, Kasyapa Chitta, Sharoon Akhtar, David Personett, Kena C. Miller, Kevin J. Thompson, Jennifer Carr, Shaji Kumar, Vivek Roy, Stephen M. Ansell, Joseph R. Mikhael, Angela Dispenzieri, Craig B. Reeder, Candido E. Rivera, James Foran & Asher Chanan-Khan. (2014) AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. British Journal of Haematology 164:3, pages 352-365.
Crossref

Chui-Ze Kong & Zhe Zhang. (2013) Bcl-2 Overexpression Inhibits Generation of Intracellular Reactive Oxygen Species and Blocks Adriamycin-induced Apoptosis in Bladder Cancer Cells. Asian Pacific Journal of Cancer Prevention 14:2, pages 895-901.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

Articles from other publishers (14)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

Citations (14)

Articles from other publishers (14)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date